EUVIMEDEUVIMED entdecken
Open Access

Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial

Jacob A Quaytman, Natalie L David, Sharini Venugopal, Tânia Amorim, Britney Beatrice, Frederico G S Toledo, Rachel G Miller, Matthew L Steinhauser, Pouneh K Fazeli

Contemporary Clinical Trials · 2024

DOI: 10.1016/j.cct.2024.107698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2024. Verfasst von Jacob A Quaytman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Caloric Restriction, Diabetes Mellitus, Type 2, Fasting, Triglycerides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Caloric restriction prolongs lifespan in model organisms and improves metrics of aging-related diseases in humans, but daily compliance is challenging. Intermittent fasting improves metrics of lipid and glucose metabolism in the setting of weight loss but whether these metrics are improved independent of weight loss is not known. METHODS: We seek to address this gap with IFAST, a single-center, three-arm, prospective, randomized, controlled clinical trial. Eligible study participants are adults with no chronic medical conditions beyond prediabetes or overweight but who are at high risk for type 2 diabetes mellitus (T2D), defined as having a history of gestational diabetes or a first-degree relative with T2D. Participants will be randomized in a 1:2:2 schema to either a control group, a fasting group, or a fasting/weight maintenance group. The fasting groups will complete a 24-h fast one day per week for 12 weeks. The key mechanistic endpoint is change in triglyceride composition (defined by carbon content and degree of saturation) as measured by longitudinal metabolomics. The key safety endpoint is percent change from baseline in bone volume fraction (BV/TV; high-resolution peripheral quantitative CT) at the radius in the fasting group. Secondary endpoints include measures of insulin sensitivity (hyperinsulinemic-euglycemic clamp), clinical lipid profiling, systemic inflammation markers, hunger assessment, bone density, and bone microarchitecture with high-resolution peripheral quantitative CT. CONCLUSION: IFAST will investigate intrinsic metabolic benefits of intermittent fasting beyond weight loss. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT05722873.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Caloric RestrictionDiabetes Mellitus, Type 2FastingTriglyceridesAdultFemaleHumansMaleMiddle AgedIntermittent FastingMetabolic ReprogrammingProspective StudiesWeight LossRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Bone metabolismInsulin resistanceIntermittent fastingRandomized controlled trialTriglyceridesWeight loss

Substanzen

Triglycerides

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Center for Human Integrative Physiology, Aging Institute, University of Pittsburgh School of Medicine, Pi…
  • Department of Sports Medicine and Nutrition, University of Pittsburgh School of Health and Rehabilitation Sciences, Pittsburgh, PA 15260, USA.
  • Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Center for Human Integrative Physiology, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Division of Cardiovascular Medicine, University of Pittsburgh School of Medicine, Pittsbu…

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • Indiana Clinical and Translational Sciences Institute
  • Clinical and Translational Science Institute, University of Pittsburgh

Zitieren

APA

Quaytman, J. A., David, N. L., Venugopal, S., Amorim, T., Beatrice, B., Toledo, F. G. S., Miller, R. G., Steinhauser, M. L., & Fazeli, P. K. (2024). Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107698

Vancouver

Quaytman JA, David NL, Venugopal S, Amorim T, Beatrice B, Toledo FGS, et al. Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial. Contemporary Clinical Trials. 2024. doi:10.1016/j.cct.2024.107698

BibTeX
@article{Quaytman2024,
  author = {Quaytman, Jacob A and David, Natalie L and Venugopal, Sharini and Amorim, Tânia and Beatrice, Britney and Toledo, Frederico G S and Miller, Rachel G and Steinhauser, Matthew L and Fazeli, Pouneh K},
  title = {Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial},
  journal = {Contemporary Clinical Trials},
  year = {2024},
  doi = {10.1016/j.cct.2024.107698}
}
Kostenlos starten →